We are live on
!
Find out more
DGM
Darwin Global Management Portfolio holdings
AUM
$3.76B
Turnover
16.67%
1-Year Est. Return
342.13%
This Fund
S&P 500
This Quarter
Est. Return
-3.24%
1 Year Est. Return
+342.13%
3 Year Est. Return
+2,581.87%
5 Year Est. Return
+47,632.22%
10 Year Est. Return
–
AUM
$3.77B
AUM Growth
-$1.17B
(-24%)
Cap. Flow
-$565M
Cap. Flow
% of AUM
-14.98%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
3
Increased
2
Reduced
1
Closed
3
Avg Time Held
0.4
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$223M |
| 2 |
Roivant Sciences
ROIV
|
+$175M |
| 3 |
Abivax
ABVX
|
+$34.3M |
| 4 |
Belite Bio
BLTE
|
+$5M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$1.01M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$635M |
| 2 |
Cidara Therapeutics
CDTX
|
+$220M |
| 3 |
Wave Life Sciences
WVE
|
+$125M |
| 4 |
Capricor Therapeutics
CAPR
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$21.3B
| $2.58B | 68.33% |
16,805,184
-4,128,093
| -20% | -$635M |
2024 Q2
7 quarters
|
|
|
2
Belite Bio
BLTE
$5.94B
| $456M | 12.1% |
3,057,412
+29,708
| +1% | +$5M |
2025 Q4
1 quarter
|
|
|
3
Abivax
ABVX
$7.8B
| $352M | 9.34% |
3,468,657
+290,156
| +9% | +$34.3M |
2025 Q3
2 quarters
|
|
|
4
Revolution Medicines
RVMD
$39B
| $205M | 5.44% |
+2,211,018
| New | +$223M |
2026 Q1
0 quarters
|
|
|
5
Roivant Sciences
ROIV
$24.3B
| $180M | 4.76% |
+6,797,300
| New | +$175M |
2026 Q1
0 quarters
|
|
|
6
Dianthus Therapeutics
DNTH
$4.04B
| $1.46M | 0.04% |
+17,357
| New | +$1.01M |
2026 Q1
0 quarters
|
|
|
7
Capricor Therapeutics
CAPR
$403M
| – | – |
-800,000
| Closed | -$23.2M | – |
|
|
8
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-997,196
| Closed | -$220M | – |
|
|
9
Wave Life Sciences
WVE
$633M
| – | – |
-7,298,421
| Closed | -$125M | – |
|
Similar funds
FAM
Darwin Global Management's Q1 2026 Portfolio in Review
As of Q1 2026, Darwin Global Management held 9 positions worth $3.77B, down 24% from $4.94B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Darwin Global Management withdrew a net $565M in Q1 2026, closing 3 positions and reducing 1 holding. Its most notable exit was Cidara Therapeutics, an estimated $220M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Darwin Global Management opened a new position in Revolution Medicines worth $205M.
- Darwin Global Management's largest Q1 2026 buy was Revolution Medicines: 2,211,018 shares worth $205M.
- Darwin Global Management added most to Abivax in Q1 2026, an estimated $34.3M increase.
- Darwin Global Management's biggest Q1 2026 reduction was Insmed, cutting an estimated $635M.
- Darwin Global Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $220M.
- Darwin Global Management's ten largest holdings make up 100% of its $3.77B portfolio in Q1 2026.
- Darwin Global Management opened 3 new positions and closed 3 in Q1 2026.
- Darwin Global Management's portfolio value fell 24% quarter-over-quarter to $3.77B.
Based on Darwin Global Management's 13F filing for Q1 2026, filed 15 May 2026.